CORD-19:0036b28fddf7e93da0970303672934ea2f9944e7 / 156649-156888 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T1262","span":{"begin":0,"end":239},"obj":"Sentence"},{"id":"T8411","span":{"begin":0,"end":239},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"We previously reported that eBAT was safe and improved overall survival for dogs with splenic hemangiosarcoma (HSA) in the minimal residual disease setting when added to standard of care (SOC) therapy in a single cycle of three treatments."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T634","span":{"begin":86,"end":109},"obj":"Disease"},{"id":"T635","span":{"begin":94,"end":109},"obj":"Disease"},{"id":"T636","span":{"begin":111,"end":114},"obj":"Disease"},{"id":"T45680","span":{"begin":86,"end":109},"obj":"Disease"},{"id":"T9601","span":{"begin":94,"end":109},"obj":"Disease"},{"id":"T66697","span":{"begin":111,"end":114},"obj":"Disease"}],"attributes":[{"id":"A634","pred":"mondo_id","subj":"T634","obj":"http://purl.obolibrary.org/obo/MONDO_0002376"},{"id":"A635","pred":"mondo_id","subj":"T635","obj":"http://purl.obolibrary.org/obo/MONDO_0016982"},{"id":"A636","pred":"mondo_id","subj":"T636","obj":"http://purl.obolibrary.org/obo/MONDO_0011848"},{"id":"A637","pred":"mondo_id","subj":"T636","obj":"http://purl.obolibrary.org/obo/MONDO_0016982"},{"id":"A40389","pred":"mondo_id","subj":"T45680","obj":"http://purl.obolibrary.org/obo/MONDO_0002376"},{"id":"A52891","pred":"mondo_id","subj":"T9601","obj":"http://purl.obolibrary.org/obo/MONDO_0016982"},{"id":"A78305","pred":"mondo_id","subj":"T66697","obj":"http://purl.obolibrary.org/obo/MONDO_0011848"},{"id":"A70878","pred":"mondo_id","subj":"T66697","obj":"http://purl.obolibrary.org/obo/MONDO_0016982"}],"text":"We previously reported that eBAT was safe and improved overall survival for dogs with splenic hemangiosarcoma (HSA) in the minimal residual disease setting when added to standard of care (SOC) therapy in a single cycle of three treatments."}